The AI medical technology company Skin Analytics has been recognised by NHSX with a Phase 4 AI in Health and Care Award. NHSX is a joint government, NHS and industry unit that was set up to create the most advanced health and care service in the world to diagnose diseases earlier, free up staff time and empower patients to take greater control of their own healthcare. The product recognised is DERM, a CE marked medical device that changes the way skin cancer is assessed and treated by the NHS by analysing dermoscopic images of skin lesions using AI algorithms, easing pressure on primary and secondary care by reducing needless referrals and has already proven its worth in University Hospitals Birmingham and in Mid and South Essex Health and Care Partnership. In the primary care setting Skin Analytics’ DERM is used as an adjunctive tool to assist GPs with their decision making around getting patients on the right pathway quicker and more effectively. In the secondary care setting DERM supports dermatologists to triage cases, discharge benign referrals earlier in the pathway and speed up cancer diagnosis. Statistics suggest that DERM has already assessed over 6,500 patients and discharged more than 1,600 benign referrals.
Consultant dermatologist at Chelsea & Westminster Hospital, Dr Lucy Thomas, said: “Skin Analytics’ receipt of this award is great news for the NHS and dermatology departments. It will allow us to gather real-world data to demonstrate the benefits of AI on patient pathways and workforce challenges. Like many services, dermatology has severe backlogs due to the COVID-19 pandemic. This award couldn't have come at a better time to aid recovery and give us more time with the patients most in need of our help.”
“Like many services, dermatology has severe backlogs due to the COVID-19 pandemic. This award couldn't have come at a better time to aid recovery and give us more time with the patients most in need of our help“
Skin Analytics’ CEO, Neil Daly, said: “The AI award is a major step forward in making DERM more widely available across the NHS. It will enable us to put our technology into the hands of GPs and clinicians around the country and allow them to assess its benefits for themselves. The key to skin cancer survival is early diagnosis, and DERM helps to prioritise patients into specialist services sooner rather than later. At the same time, we can more effectively manage the sharply rising demand for dermatology services with the workforce we have.”